John E. Bishop - Feb 27, 2023 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
Chief Technology Officer
Signature
/s/ Jason Cavalier, Attorney-in-Fact for John E. Bishop
Stock symbol
LYRA
Transactions as of
Feb 27, 2023
Transactions value $
$0
Form type
4
Date filed
2/28/2023, 03:10 PM
Previous filing
Oct 14, 2022
Next filing
Feb 1, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Stock Option Award $0 +220K $0.00 220K Feb 27, 2023 Common Stock 220K $2.31 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests and becomes exercisable as to 25% of the underlying shares on February 27, 2024 and in 36 substantially equal monthly installments thereafter.